Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Clinical and Experimental Immunology|May 3, 2002
Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugsG Strauss, W Osen, K-M DebatinJournal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 25, 2000
Immunization against human papillomavirus infection and associated neoplasiaW Osen, I Jochmus, M Müller, et al.Intervirology|August 18, 2001
Therapeutic vaccines for human papillomavirusesL Gissmann, W Osen, M Müller, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 14, 1999
Alloreactivity as a source of high avidity peptide-specific human CTLC Münz, R Obst, W Osen, et al.Archives of Virology|September 15, 1999
E7-specific cytotoxic T cell tolerance in HPV-transgenic miceA Borchers, J Braspenning, J Meijer, et al.Cell Death and Differentiation|August 12, 2006
Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunityG Strauss, W Osen, I Knape, et al.The Journal of General Virology|July 1, 1997
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptideI Jochmus, W Osen, A Altmann, et al.International Journal of Cancer|June 11, 1999
Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protectionK Schäfer, M Müller, S Faath, et al.Archives of Virology|January 1, 1996
Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in cultureA Hoos, C D'Incan, L Gissmann, et al.Vaccine|July 18, 2001
A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activityW Osen, T Peiler, P Ohlschläger, et al.Pageof 2